Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Justin Ritz, Robert A. Salata et al.|The Lancet HIV|2019Cited by 39
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D. Hughes, Robert A. Salata et al.|Journal of the International AIDS Society|2022Cited by 13